PF-04523655 is a chemically-modified siRNA drug candidate being co-developed by Quark and Pfizer for the treatment of wet age-related macular degeneration (wet-AMD) and diabetic macular edema (DME). According
R-Tech Ueno said that the FDA inspected the Sanda factory in December 2009. By passing this inspection, Rescula Eye Drops (unoprostone isopropyl eye drops) manufactured at this factory
The study demonstrated that single intravenous doses of 1 and 3mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2mcg for subsequent
Oramed Pharmaceuticals said that the randomised, double-blind, placebo-controlled, multi-centered study conducted in South Africa evaluated responses of 29 type 2 diabetes patients to ORMD-0801. Insulin-loaded or placebo capsules
Amira Pharmaceuticals said that the LPA1 receptor is part of the phosphatidic acid/ lysophosphatidylcholine pathway and has recently been implicated for having a role in lung, kidney and
BioInvent International and ThromboGenics said that the Phase II results demonstrate that TB-402 has superior antithrombotic activity to enoxaparin with comparable safety. Enoxaparin is currently the standard treatment
Intellipharmaceutics, Par, Novartis Pharmaceuticals, Novartis Pharma, Celgene, Elan and Elan Pharma, have also entered into license agreements in conjunction with the settlements of the litigation concerning the company’s
URL Pharma said that these new dosing recommendations were issued as a result of several clinical studies designed and conducted by URL Pharma that uncovered the risk of
Nortech Systems said that the Milaca operation specialises in design, manufacturing and post-production services of complex electronic and electromechanical medical devices for diagnostic, analytical and other life-science applications.
Vetter will fill early-stage, high-value biopharmaceuticals at its Chicago facility; Sentry will label, package and ship the clinical supplies from its site in Indianapolis, Indiana. The collaboration will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.